Skye Bioscience price to book ratio SKYE

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.0×; Aug 2026
7-year median: 2.9×
7-year range: 0.6× to 122×
Peer median: 1.5×

Skye Bioscience's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2026, at 2.0×.

On the days it had one over the last 7 years, its median was 2.9×, from 0.6× in Apr 2025 to 122× in Mar 2024.

Price to book ratio over time

median 2.9×

The dashed line is the 7-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.0×	0.7×	3.2×
2025	0.8×	0.6×	3.4×
2024	1.0×	1.0×	122×
2023	19.8×	11.3×	25.5×
2022	5.3×	1.8×	7.5×
2021	3.0×	3.0×	96.3×
2020	5.4×	4.0×	30.4×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	63.9×	51.5×	160×
2014	165×	165×	185×

Against its peers

Companies in Healthcare nearest Skye Bioscience's size, closest first, today.

Company	Price to book ratio
SKYESkye Bioscience	n/m
NEPHNephros	3.2×
ATNMActinium Pharmaceuticals	1.6×
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.5×
Peer median	1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Skye Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.